Expiratory Positive Expiratory Pressure (EPAP) enhanced Mandibular Advancement Device (MAD) is well tolerated with minor adverse effects

<bold>Introduction:</bold> The ExVent is an accessory to the O2Vent Optima mandibular advancement device (MAD) and provides oral Expiratory Positive Airway Pressure (EPAP). Oral EPAP with the ExVent is designed to augment the OSA therapy provided by the O2Vent Optima. Long term complications and adverse effects associated with this combination therapy are not known, but require inquiry. <bold>Methods:</bold> A retrospective survey was conducted of all patients who received O2Vent Optima MAD and ExVent in Canada and Australia since 2019. Data collected following consent included: demographics, duration of use, frequency of use, complications and adverse events. <bold>Results:</bold> Out of the 480 patients, 168 (35%) could be contacted and agreed to participate. 31 (18%) had stopped using the appliance. Out of 137 (81%) subjects, 118 (86%) were still using the ExVent Accessory, 92% medium strength (Yellow). 56% used morning aligner and 74% performed regular jaw exercises. After 4 weeks of the device use, excessive salivation was (12%), tooth and jaw pain were reported occasionally (8%), tooth movement was none (0%). Gum or tongue bruises (0%). TMJ pain/stiffness (5%). Change in bite or occlusion leading to discontinuation (0%), temporary chewing difficulties (24%) and dry mouth (0%). Difficulty to insert or remove ExVent valve (0%), difficulty breathing (0%), Malfunctioning or dislodgement of ExVent valve (0%). Participants reportedly valued their device (94%) and benefited with ExVent (100%). <bold>Conclusion:</bold> Majority of the patients prescribed O2Vent Optima and ExVent accessory were compliant, demonstrated no significant complications and had minor adverse effects with the combination therapy.

Authors

Institutions

Publication Details

Published
2024-09-14
DOI
https://doi.org/10.1183/13993003.congress-2024.pa864
Primary Topic
Tracheal and airway disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Expiratory Positive Expiratory Pressure (EPAP) enhanced Mandibular Advancement Device (MAD) is well tolerated with minor adverse effects

Barry Weinstein, Bruce A. Smith, Antonella Conflitti, Hilary Reiter et al.
Tracheal and airway disorders
article

Expiratory Positive Expiratory Pressure (EPAP) enhanced Mandibular Advancement Device (MAD) is well tolerated with minor adverse effects

Barry Weinstein, Bruce A. Smith, Antonella Conflitti, Hilary Reiter, Ivan Valcarenghi, Shideh Pejman, Sat Sharma, Adam Teo, Bob Gibbons
article en

Abstract

<bold>Introduction:</bold> The ExVent is an accessory to the O2Vent Optima mandibular advancement device (MAD) and provides oral Expiratory Positive Airway Pressure (EPAP). Oral EPAP with the ExVent is designed to augment the OSA therapy provided by the O2Vent Optima. Long term complications and adverse effects associated with this combination therapy are not known, but require inquiry. <bold>Methods:</bold> A retrospective survey was conducted of all patients who received O2Vent Optima MAD and ExVent in Canada and Australia since 2019. Data collected following consent included: demographics, duration of use, frequency of use, complications and adverse events. <bold>Results:</bold> Out of the 480 patients, 168 (35%) could be contacted and agreed to participate. 31 (18%) had stopped using the appliance. Out of 137 (81%) subjects, 118 (86%) were still using the ExVent Accessory, 92% medium strength (Yellow). 56% used morning aligner and 74% performed regular jaw exercises. After 4 weeks of the device use, excessive salivation was (12%), tooth and jaw pain were reported occasionally (8%), tooth movement was none (0%). Gum or tongue bruises (0%). TMJ pain/stiffness (5%). Change in bite or occlusion leading to discontinuation (0%), temporary chewing difficulties (24%) and dry mouth (0%). Difficulty to insert or remove ExVent valve (0%), difficulty breathing (0%), Malfunctioning or dislodgement of ExVent valve (0%). Participants reportedly valued their device (94%) and benefited with ExVent (100%). <bold>Conclusion:</bold> Majority of the patients prescribed O2Vent Optima and ExVent accessory were compliant, demonstrated no significant complications and had minor adverse effects with the combination therapy.

Seqwater (AU), Fleming College (CA), Australian Dental Association (AU), Health Sciences Centre (CA), Toronto Sleep Institute (CA), Smile Train (US), Elmhurst University (US)
Openalex Percentile: Top 63%
Tracheal and airway disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.